National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedMontgomery KB, Holder AM, Burgan CM
Is it time for synoptic reporting in melanoma nodal surveillance ultrasonography?
Previous qualitative research has identified a potential gap between surgeons’ and radiologists’ awareness of Second Multicenter Selective Lymphadenectomy Trial (MSLT-II) criteria. The purpose of this study was to explore how these criteria have been adopted and reported outside of clinical trial settings or utilized by surgical teams when interpreting ultrasound results. The study found that of the 269 nodal ultrasounds performed in 78 patients, 81.0% reported normal findings versus 19% abnormal findings. Researchers indicated that only 15% of normal ultrasounds had one or more MSLT-II criteria reported versus 88.9% abnormal ultrasounds. While 37% of abnormal ultrasounds had only one MSLT-II criterion reported, 27.8% had two criteria and 24.1% had three criteria. Of the eight abnormal ultrasounds with biopsy recommendation, 75% had two or more MSLT-II criteria reported. Clinically actionable recommendations were provided in 94.9% of normal ultrasounds compared with 64.8% of abnormal ultrasounds.
AHRQ-funded; HS013852.
Citation: Montgomery KB, Holder AM, Burgan CM .
Is it time for synoptic reporting in melanoma nodal surveillance ultrasonography?
Ann Surg Oncol 2023 Sep; 30(9):5327-28. doi: 10.1245/s10434-023-13749-0..
Keywords: Cancer: Skin Cancer, Cancer, Skin Conditions, Imaging
Huo J, Lairson DR, Du XL
Survival and cost-effectiveness of hospice care for metastatic melanoma patients.
The authors analyzed the association of hospice use with survival and health care costs among patients diagnosed with metastatic melanoma. They found that the median survival time was 6.1 months for patients with no hospice care, 6.5 months for patients enrolled in hospice for 1 to 3 days, and 10.2 months for patients enrolled for 4 or more days. Patients with 4 or more days of hospice care incurred lower end-of-life costs than the comparison groups.
AHRQ-funded; HS018956.
Citation: Huo J, Lairson DR, Du XL .
Survival and cost-effectiveness of hospice care for metastatic melanoma patients.
Am J Manag Care 2014 May;20(5):366-73.
.
.
Keywords: Cancer, Cancer: Skin Cancer, Healthcare Costs, Palliative Care, Patient-Centered Outcomes Research